▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Bayer Korea on April 17 announced the names of three startups who have been selected for its open innovation program in consultation with KOTRA. This is the second round of Grants4Ap...
[THE INVESTOR] South Korean drugmakers are rushing to roll out generic copies of Pfizer’s smoking cessation drug Champix, as the treatment’s substance patent here was recently broken by a local pate...
[THE INVESTOR] Humedix, a subsidiary of Huons Global , said on April 16 that it has obtained sales approval for two types of injection therapies that repair damaged skin and encourage wound healin...
[THE INVESTOR] Chong Kun Dang Pharmaceutical said on April 16 that it has entered into a partnership with the Japanese unit of a US-based drug maker to export its biosimilar candidate referencing Ky...
[THE INVESTOR] Hanmi Pharmaceutical said on April 13 that it is abandoning the development of Olita, its new lung cancer treatment, as a rival drug has already hit the markets. “We found it difficu...
[THE INVESTOR] Korean stem cell therapy firm CHA Biotech said on April 12 it will set up a new subsidiary to spin off its contract drug manufacturing and basic research business to improve its bal...
[THE INVESTOR] SK Chemicals, the chemical and biopharmaceutical arm of SK Group, has picked a name for the vaccine unit it is planning to spin off this year, a company official said on April 12. Th...
[THE INVESTOR] Daewoong Pharmaceutical said on April 11 it has opened a research center in Indonesia to expand its global network. Located in the University of Indonesia, the Bio Technology Resear...
[THE INVESTOR] ToolGen , Korea’s biotech specialized in genome editing, expects its market capitalization to exceed 1 trillion won (US$938 million) if its stock transfers to the bigger KOSDAQ marke...
[THE INVESTOR] Samsung C&T , the de facto holding firm of Samsung Group, on April 10 denied news reports that it is considering buying shares in its sister biopharmaceutical unit Samsung Bioepis in...
[THE INVESTOR] Samsung BioLogics’ market value has surpassed that of its crosstown rival Celltrion for the first time, becoming the nation’s third most valuable company only behind Samsung Electron...
[THE INVESTOR] Bukwang Pharmaceutical said on April 9 that it has started patient dosing for its pivotal phase 3 clinical trials of schizophrenia therapy Lurasidone that it licensed from a Japanese...
[THE INVESTOR] The US Food and Drug Administration’s decision to turn down Celltrion’s applications for two biosimilar candidates will disrupt the timing of approvals but their launch schedule is li...
[THE INVESTOR] Celltrion has faced a setback in bringing its two biosimilar products to the US market as authorities have decided not to approve them for now. The Korean company said on April 5 th...
[THE INVESTOR] GC Pharma said on April 5 that the first patient was dosed in its phase 1b/2a clinical trials of cancer drug candidate GC1118. GC1118, an anti-epidermal growth factor receptor monoc...
[INTERVIEW] Don’t skimp a thing to lose weight, says Dano founder
Memebox signs partnership deal with Sephora
Joonggonara receives W5b investment from JB Woori Capital, Kiwoom Securities
Costco Korea may ditch 18-year partnership with Samsung Card
National Pension Service at crossroads with lackluster returns
ToolGen to relist on KOSDAQ
YD Global Life Science set to begin phase 2a trials of diabetic retinopathy drug
Samsung butts heads with LG in clothing care system market
August 22, 2018
![[INTERVIEW] Don’t skimp a thing to lose weight, says Dano founder](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=152&simg=/content/image/2018/08/21/20180821000796_0.jpg&md=20180821165108)
